Cargando…
A Potential Involvement of Anandamide in the Modulation of HO/NOS Systems: Women, Menopause, and “Medical Cannabinoids”
Endocannabinoids and their receptors are present in the cardiovascular system; however, their actions under different pathological conditions remain controversial. The aim of our study was to examine the effects of anandamide (AEA) on heme oxygenase (HO) and nitric oxide synthase (NOS) systems in an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699915/ https://www.ncbi.nlm.nih.gov/pubmed/33233803 http://dx.doi.org/10.3390/ijms21228801 |
_version_ | 1783616158320033792 |
---|---|
author | Szabó, Renáta Börzsei, Denise Szabó, Zsuzsanna Hoffmann, Alexandra Zupkó, István Priksz, Dániel Kupai, Krisztina Varga, Csaba Pósa, Anikó |
author_facet | Szabó, Renáta Börzsei, Denise Szabó, Zsuzsanna Hoffmann, Alexandra Zupkó, István Priksz, Dániel Kupai, Krisztina Varga, Csaba Pósa, Anikó |
author_sort | Szabó, Renáta |
collection | PubMed |
description | Endocannabinoids and their receptors are present in the cardiovascular system; however, their actions under different pathological conditions remain controversial. The aim of our study was to examine the effects of anandamide (AEA) on heme oxygenase (HO) and nitric oxide synthase (NOS) systems in an estrogen-depleted rat model. Sham-operated (SO) and surgically induced estrogen-deficient (OVX) female Wistar rats were used. During a two-week period, a group of OVX rats received 0.1 mg/kg estrogen (E(2)) per os, while AEA-induced alterations were analyzed after two weeks of AEA treatment at the dose of 1.0 mg/kg. At the end of the experiment, cardiac activity and expression of HO and NOS enzymes, content of cannabinoid 1 receptor, as well as concentrations of transient potential vanilloid 1 (TRPV1) and calcitonin gene-related peptide (CGRP) were measured. Our results show that estrogen withdrawal caused a significant decrease in both NOS and HO systems, and a similar tendency was observed regarding the TRPV1/CGRP pathway. Two weeks of either AEA or E(2) treatment restored the adverse changes; however, the combined administration of these two molecules did not result in a further improvement. In light of the potential relationship between AEA and HO/NOS systems, AEA-induced upregulation of HO/NOS enzymes may be a therapeutic strategy in estrogen-deficient conditions. |
format | Online Article Text |
id | pubmed-7699915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76999152020-11-29 A Potential Involvement of Anandamide in the Modulation of HO/NOS Systems: Women, Menopause, and “Medical Cannabinoids” Szabó, Renáta Börzsei, Denise Szabó, Zsuzsanna Hoffmann, Alexandra Zupkó, István Priksz, Dániel Kupai, Krisztina Varga, Csaba Pósa, Anikó Int J Mol Sci Article Endocannabinoids and their receptors are present in the cardiovascular system; however, their actions under different pathological conditions remain controversial. The aim of our study was to examine the effects of anandamide (AEA) on heme oxygenase (HO) and nitric oxide synthase (NOS) systems in an estrogen-depleted rat model. Sham-operated (SO) and surgically induced estrogen-deficient (OVX) female Wistar rats were used. During a two-week period, a group of OVX rats received 0.1 mg/kg estrogen (E(2)) per os, while AEA-induced alterations were analyzed after two weeks of AEA treatment at the dose of 1.0 mg/kg. At the end of the experiment, cardiac activity and expression of HO and NOS enzymes, content of cannabinoid 1 receptor, as well as concentrations of transient potential vanilloid 1 (TRPV1) and calcitonin gene-related peptide (CGRP) were measured. Our results show that estrogen withdrawal caused a significant decrease in both NOS and HO systems, and a similar tendency was observed regarding the TRPV1/CGRP pathway. Two weeks of either AEA or E(2) treatment restored the adverse changes; however, the combined administration of these two molecules did not result in a further improvement. In light of the potential relationship between AEA and HO/NOS systems, AEA-induced upregulation of HO/NOS enzymes may be a therapeutic strategy in estrogen-deficient conditions. MDPI 2020-11-20 /pmc/articles/PMC7699915/ /pubmed/33233803 http://dx.doi.org/10.3390/ijms21228801 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Szabó, Renáta Börzsei, Denise Szabó, Zsuzsanna Hoffmann, Alexandra Zupkó, István Priksz, Dániel Kupai, Krisztina Varga, Csaba Pósa, Anikó A Potential Involvement of Anandamide in the Modulation of HO/NOS Systems: Women, Menopause, and “Medical Cannabinoids” |
title | A Potential Involvement of Anandamide in the Modulation of HO/NOS Systems: Women, Menopause, and “Medical Cannabinoids” |
title_full | A Potential Involvement of Anandamide in the Modulation of HO/NOS Systems: Women, Menopause, and “Medical Cannabinoids” |
title_fullStr | A Potential Involvement of Anandamide in the Modulation of HO/NOS Systems: Women, Menopause, and “Medical Cannabinoids” |
title_full_unstemmed | A Potential Involvement of Anandamide in the Modulation of HO/NOS Systems: Women, Menopause, and “Medical Cannabinoids” |
title_short | A Potential Involvement of Anandamide in the Modulation of HO/NOS Systems: Women, Menopause, and “Medical Cannabinoids” |
title_sort | potential involvement of anandamide in the modulation of ho/nos systems: women, menopause, and “medical cannabinoids” |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699915/ https://www.ncbi.nlm.nih.gov/pubmed/33233803 http://dx.doi.org/10.3390/ijms21228801 |
work_keys_str_mv | AT szaborenata apotentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT borzseidenise apotentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT szabozsuzsanna apotentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT hoffmannalexandra apotentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT zupkoistvan apotentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT prikszdaniel apotentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT kupaikrisztina apotentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT vargacsaba apotentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT posaaniko apotentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT szaborenata potentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT borzseidenise potentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT szabozsuzsanna potentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT hoffmannalexandra potentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT zupkoistvan potentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT prikszdaniel potentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT kupaikrisztina potentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT vargacsaba potentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids AT posaaniko potentialinvolvementofanandamideinthemodulationofhonossystemswomenmenopauseandmedicalcannabinoids |